NCT06285890View on ClinicalTrials.gov

Phase I Study of HC-7366 for Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

HC-7366

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

HiberCell, Inc.

All Listed Sponsors

collaborator

HiberCell, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER